Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
October 07 2019 - 8:00AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage company and
leader in gene therapy using non-viral vector transfection
delivery, wishes to draw attention to additional research in the
field validating non-viral vector delivery as the next evolution in
gene therapy.
A recently published paper by researchers in Australia, Spain
and Austria supports the belief that non-viral delivery could be
safer for patients than viral vectors and could speed up the
production time while reducing the costs of production. The paper
titled, “Encapsulation, Visualization and Expression of Genes with
Biomimetically Mineralized Zeolitic Imidazolate Framework-8
(ZIF-8)” published in the September 4, 2019 issue of the scientific
journal Small, presents data from a biomolecule-metal-organic
framework (nano MOF) in zeolitic imidazolate framework-8 (ZIF-8)
and found it to be a viable vehicle for intracellular transfection
and gene delivery. Genprex was not involved in the study, which
used a different nanotechnology.
“One of the biggest differentiators between Genprex and other
gene therapy companies developing technologies to treat cancer and
other serious diseases is our proprietary non-viral nanoparticle
delivery system, which has already been used to safely treat more
than 50 patients to date,” said Genprex’s Chairman and Chief
Executive Officer, Rodney Varner. “Most gene therapy research has
been focused on using viral delivery systems to deliver genes to
cancer cells, and today most approved gene therapies for non-blood
cell therapies use a viral vector to deliver the gene to the
patient. Our proprietary non-viral delivery system enables us to
potentially treat patients with a system that may be safer, with
lower production costs and better scalability.”
Based on the shortcomings that viral vectors have historically
had, including severe adverse reactions, high production costs,
difficulty in scaling and high immunogenicity responses, Genprex’s
founders partnered with the National Institutes of Health (NIH)
during the company’s inception to develop its proprietary non-viral
delivery system.
Specifically, Genprex’s platform technologies are designed to
administer cancer fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then
administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities. The
nanovesicles are non-immunogenic, allowing repetitive therapeutic
dosing. Genprex’s nanovesicles are also clinically proven to
effectively deliver molecular kinase inhibitors effectively.
A Phase I human clinical trial showed that Genprex’s lead drug
candidate, Oncoprex™ immunogene therapy, which is delivered through
its nanovesicle non-viral delivery system, selectively and
preferentially targeted primary and metastatic tumor cells,
resulting in clinically significant anticancer activity. Genprex’s
clinical trials have also demonstrated that its delivery system is
well tolerated in humans and can safely deliver high therapeutic
doses.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. For more information, please visit the company’s web
site at www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer and the safety, production cost
and scalability of Oncoprex and its non-viral delivery system.
Risks that contribute to the uncertain nature of the
forward-looking statements include the presence and level of
Oncoprex’s effect on cancer, the safety, cost and scalability of
Oncoprex and its delivery system, as well as the timing and success
of our clinical trials and planned clinical trials, Oncoprex™ and
our other potential product candidates. These and other risks and
uncertainties associated with Genprex and its lead product
candidate Oncoprex are described more fully under the caption “Risk
Factors” and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005150/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024